Current Concepts in the Management of Relapsed/Refractory Multiple Myeloma: Considerations With Bispecific Anti-BCMA Antibodies
Podcast 3: Managing Relapsed/Refractory Multiple Myeloma: Considerations for Newer Therapies

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
In a patient who has developed resistance to at least four courses of multiple myeloma therapy, an FDA-approved agent or clinical trial of an investigational agent from which of the following classes would be most appropriate?
Brett is a 67-year-old man with multiple myeloma. He has previously received a proteasome inhibitor, an immunomodulatory agent, a CD38-targeting monoclonal antibody, and an alkylating agent, but he currently presents with another relapse. Which of the following approaches would you take for this patient at this time? 
Powered by QuestionPro